The modified scFvs recognize either prostate stem cell antigen (PSCA), a prostate cancer (PCa) specific antigen [26], [27] or CD33, a cell surface glycoprotein specific for hematopoietic cells of myeloid origin [28]. Here, CD33 is linked to posterior cortical atrophy.